As a result of the fact that BRD4 demonstrates YAP/TAZ‐independent transcriptional activity, combined YAP/TAZ/BRD4 targeting could also address the full extent of the tumour mechanosignaling‐engaged impact on cancer progression.9 The gene discussed is YAP1; the disease is neoplasm.